397 related articles for article (PubMed ID: 12496059)
1. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy.
Jacob P; Hatsukami D; Severson H; Hall S; Yu L; Benowitz NL
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1668-73. PubMed ID: 12496059
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of the Minor Tobacco Alkaloids Nornicotine, Anatabine, and Anabasine in Smokers' Urine by High Throughput Liquid Chromatography-Mass Spectrometry.
von Weymarn LB; Thomson NM; Donny EC; Hatsukami DK; Murphy SE
Chem Res Toxicol; 2016 Mar; 29(3):390-7. PubMed ID: 26825008
[TBL] [Abstract][Full Text] [Related]
3. Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes.
Jacob P; Yu L; Shulgin AT; Benowitz NL
Am J Public Health; 1999 May; 89(5):731-6. PubMed ID: 10224986
[TBL] [Abstract][Full Text] [Related]
4. A one-year monitoring of nicotine use in sport: frontier between potential performance enhancement and addiction issues.
Marclay F; Grata E; Perrenoud L; Saugy M
Forensic Sci Int; 2011 Dec; 213(1-3):73-84. PubMed ID: 21719221
[TBL] [Abstract][Full Text] [Related]
5. Gas chromatographic-mass spectrometric method for determination of anabasine, anatabine and other tobacco alkaloids in urine of smokers and smokeless tobacco users.
Jacob P; Yu L; Liang G; Shulgin AT; Benowitz NL
J Chromatogr; 1993 Sep; 619(1):49-61. PubMed ID: 8245163
[TBL] [Abstract][Full Text] [Related]
6. Anabasine and Anatabine Exposure Attributable to Cigarette Smoking: National Health and Nutrition Examination Survey (NHANES) 2013-2014.
Bendik PB; Rutt SM; Pine BN; Sosnoff CS; Blount BC; Zhu W; Feng J; Wang L
Int J Environ Res Public Health; 2022 Aug; 19(15):. PubMed ID: 35955098
[TBL] [Abstract][Full Text] [Related]
7. Nicotine-like behavioral effects of the minor tobacco alkaloids nornicotine, anabasine, and anatabine in male rodents.
Caine SB; Collins GT; Thomsen M; Wright C; Lanier RK; Mello NK
Exp Clin Psychopharmacol; 2014 Feb; 22(1):9-22. PubMed ID: 24490708
[TBL] [Abstract][Full Text] [Related]
8. Enantiomeric analysis of anatabine, nornicotine and anabasine in commercial tobacco by multi-dimensional gas chromatography and mass spectrometry.
Liu B; Chen C; Wu D; Su Q
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Apr; 865(1-2):13-7. PubMed ID: 18342587
[TBL] [Abstract][Full Text] [Related]
9. Novel proposed cutoff values for anatabine and anabasine in differentiating smokers from non-smokers.
Colsoul ML; Goderniaux N; Onorati S; Dupuis S; Jamart J; Vanpee D; Berlin I; Galanti L
Clin Biochem; 2023 Jun; 116():128-131. PubMed ID: 37146788
[TBL] [Abstract][Full Text] [Related]
10. Effects of treatment on cardiovascular risk among smokeless tobacco users.
Allen SS; Hatsukami D; Jensen J; Grillo M; Bliss R
Prev Med; 1995 Jul; 24(4):357-62. PubMed ID: 7479625
[TBL] [Abstract][Full Text] [Related]
11. Validation of a LC-MS/MS method for quantifying urinary nicotine, six nicotine metabolites and the minor tobacco alkaloids--anatabine and anabasine--in smokers' urine.
McGuffey JE; Wei B; Bernert JT; Morrow JC; Xia B; Wang L; Blount BC
PLoS One; 2014; 9(7):e101816. PubMed ID: 25013964
[TBL] [Abstract][Full Text] [Related]
12. A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers.
Murphy SE; Link CA; Jensen J; Le C; Puumala SS; Hecht SS; Carmella SG; Losey L; Hatsukami DK
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1617-23. PubMed ID: 15466978
[TBL] [Abstract][Full Text] [Related]
13. Smoking cessation with smokeless tobacco and group therapy: an open, randomized, controlled trial.
Tønnesen P; Mikkelsen K; Bremann L
Nicotine Tob Res; 2008 Aug; 10(8):1365-72. PubMed ID: 18686184
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles.
Moyer TP; Charlson JR; Enger RJ; Dale LC; Ebbert JO; Schroeder DR; Hurt RD
Clin Chem; 2002 Sep; 48(9):1460-71. PubMed ID: 12194923
[TBL] [Abstract][Full Text] [Related]
15. Smokeless tobacco cessation: report of a preliminary trial using nicotine chewing gum.
Sinusas K; Coroso JG
J Fam Pract; 1993 Sep; 37(3):264-7. PubMed ID: 8409878
[TBL] [Abstract][Full Text] [Related]
16. Reference interval determination for anabasine: a biomarker of active tobacco use.
Suh-Lailam BB; Haglock-Adler CJ; Carlisle HJ; Ohman T; McMillin GA
J Anal Toxicol; 2014 Sep; 38(7):416-20. PubMed ID: 24939383
[TBL] [Abstract][Full Text] [Related]
17. [What are the markers of tobacco smoking?].
Gourlain H; Galliot-Guilley M
J Gynecol Obstet Biol Reprod (Paris); 2005 Apr; 34 Spec No 1():3S154-70. PubMed ID: 15980785
[TBL] [Abstract][Full Text] [Related]
18. Determination of nicotine, cotinine, and related alkaloids in human urine and saliva by automated in-tube solid-phase microextraction coupled with liquid chromatography-mass spectrometry.
Kataoka H; Inoue R; Yagi K; Saito K
J Pharm Biomed Anal; 2009 Jan; 49(1):108-14. PubMed ID: 19004590
[TBL] [Abstract][Full Text] [Related]
19. Anabasine-based measurement of cigarette consumption using wastewater analysis.
Bade R; White JM; Tscharke BJ; Ghetia M; Abdelaziz A; Gerber C
Drug Test Anal; 2020 Sep; 12(9):1393-1398. PubMed ID: 32506745
[TBL] [Abstract][Full Text] [Related]
20. Residential treatment for smokeless tobacco use: a case series.
Ebbert JO; Dale LC; Vickers KS; Gauvin TR; Bunge NE; Hurt RD
J Subst Abuse Treat; 2004 Jun; 26(4):261-7. PubMed ID: 15182890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
